Mentice reports Q2 2026 growth and profitability
The company announced two orders worth USD 2.4M from a top MedTech firm.
See the latest news and media coverage for Mentice. We track all announcements, press releases, and industry mentions in real time, all in one place.
Medical simulation solutions for image-guided interventional therapies
mentice.comLast updated
In short: Mentice reported significant Q2 2026 financial growth and profitability, highlighted by a 25.5% sales increase and major MedTech orders.
The company announced two orders worth USD 2.4M from a top MedTech firm.
Net sales grew 25.5% to 79.6 MSEK, EBITDA improved to 6.3 MSEK, and order intake rose 36.6%.
It allows importing real patient aneurysm DICOM data for procedural simulation in under five minutes.
The orders are for simulation solutions in interventional cardiology focused on structural heart disease.
Mentice AB (FRA:MN2) reports a 28% revenue increase and significant order intake growth, driven by strategic initiatives and partnerships.
Mentice, which is a supplier of simulation technology for surgeons, reports an EBITDA result for the second quarter of 2026 of SEK 6.3 million (-8.1).
At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage...
Mentice AB (publ), a globally recognized leader in simulation solutions for image-guided therapies, today announced the receipt of two orders in total value of $2.4M...
Track Mentice and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Mentice and other trending companies.